The Effects of Antihypertensive Drugs on Bone Mineral Density in Ovariectomized Mice

Kwi Young Kang,1,2* Yoongoo Kang,1* Mininae Kim,1 Hyoju Yi,2 Juyoun Kim,2 Hae-Rin Jung,2 Sung-Kwan Park,1 Ho-Young Kim,1 Ji Hyeon Ju,1,2 and Yeon Sik Hong1

1Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, Seoul; 2Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, Korea

*Kwi Young Kang and Yoongoo Kang contributed equally to this study.

INTRODUCTION

Osteoporosis is characterized by an increase in bone fragility, resulting in fractures caused by minor trauma or even of a spontaneous nature. The disease is classified clinically as either primary or secondary osteoporosis. Primary osteoporosis is bone loss that occurs in postmenopausal women during normal aging. Postmenopausal osteoporosis, the most common form of the disease, commences when estrogen production decreases (1). Approximately forty percent of women over 50 years of age will suffer a fracture related to postmenopausal osteoporosis during their lifetime (2).

The prevalence of hypertension also increases markedly with aging, suggesting that hypertension and osteoporosis coexist. Because antihypertensive drugs are widely used for the treatment of hypertension, it is important to understand the effects of these drugs on bone. Antihypertensive drugs impact osteoporosis directly and indirectly by affecting bone metabolism, strength and density (3). Meta- and epidemiological analyses of national databases illustrate an association between antihypertensive drugs and bone function (4-7). A reduced fracture risk has been reported with thiazide diuretics (5, 6), whereas conflicting results have been reported in other antihypertensive drugs (4-7).

There are few studies on the effects of antihypertensive drugs on bone function in animal models of postmenopausal osteoporosis. Ovariectomized (OVX) mice represent an animal model that mimics postmenopausal osteoporosis in humans. We used this model to investigate whether antihypertensive drugs affect bone density and cause micro-architectural changes that associate with estrogen deficiency.

MATERIALS AND METHODS

Animals and drug treatment
Forty eight 8-week-old female C57/BL6 mice weighing 18-20 g
were purchased from Orient Bio (Seongnam, Korea). C57/BL6 mice were anesthetized by inhalation of 2% isoflurane. Bilateral ovariectomy was performed, and mice were sacrificed 5 weeks after surgery by an overdose of anesthetics. Uterine atrophy confirmed estrogen deficiency. Three days after ovariectomy, mice were treated intraperitoneally with different antihypertensive drugs for 35 consecutive days. Mice were randomly divided into 6 groups (n = 8 for each group) as follows: group 1, control (vehicle-treated); group 2, nifedipine (15 mg/kg body weight [b.w.]); group 3, telmisartan (5 mg/kg b.w.); group 4, enalapril (20 mg/kg b.w.); group 5, propranolol (1 mg/kg b.w.); and group 6, hydrochlorothiazide (12.5 mg/kg b.w.). Mice were housed in standard cages (4 mice per cage), and maintained at 22°C ± 5°C with constant humidity 50% ± 10% and a 12 hr light: 12 hr dark cycle. Animals had free access to autoclaved water and pellet diet. This experiment was conducted in accordance with institutional guidelines.

Reagents
Nifedipine, enalapril maleate, telmisartan, propranolol and hydrochlorothiazide were purchased from Sigma-Aldrich (St. Louis, MO, USA). All drugs were dissolved in dimethyl sulfoxide (DMSO).

Bone mineral density and morphometry measurements
Bone mineral density (BMD) and morphometric analyses were performed on fixed proximal tibias by micro-computed tomography (micro-CT) using a SkyScan 1172 (SkyScan, Aartselaar, Belgium). BMD (mg/cm³) was measured 0.3-0.8 mm distal to the growth plate of tibial proximal ends and analyzed in 77 continuous sections. Samples were fixed in 3.7% formaldehyde (w/v) for approximately 24 hr, and scanned at 141 A/70 kVp for 590 ms through a 0.5 mm-thick filter. Description and nomenclature followed guidelines for the assessment of bone microstructure with micro-CT analysis (8). To set the trabecular bone region consistently across samples, data from each sample were resampled with CTAn software (SkyScan) after reconstructing scanned images with SkyScan reconstruction program NRecon software. Morphometric parameters, including total volume (TV, μL), bone volume (BV, μL), bone volume fraction (BV/TV, %), trabecular thickness (Tb. Th, μm), trabecular number (Tb. N/mm) and connectivity density (Conn D/μL) were measured with CTAn software. Morphometric quantification was determined 0.3-0.8 mm distal to the growth plate of tibial proximal ends.

Statistical analyses
Statistical analyses were performed using SPSS software (version 18.0). Data are presented as mean values with standard deviation (SD). The effects of different antihypertensive drugs on BMD were analyzed by one-way analysis of variance (ANOVA), followed by Dunnett’s test (post hoc analysis). Differences between two groups were analyzed by the independent t-test or Mann-Whitney test (two-tailed) as appropriate. Correlations between parameters are presented as Spearman’s correlation coefficient (r). P values of < 0.05 were considered significant.

RESULTS
To study the effects of antihypertensive drugs on BMD in postmenopausal women, we used an ovariectomy mouse model of estrogen deficiency. Five weeks after bilateral ovariectomy, BMD was measured in tibial proximal ends of OVX mice (Fig. 1A). Except for thiazide, which significantly increased BMD (P = 0.048), there were no significant differences in BMD in drug-treated OVX mice compared with vehicle-treated OVX mice (Fig. 1B).

To investigate differences in BMD based on the severity of estrogen deficiency, OVX mice were divided into two subgroups, those with normal uteri and those with atrophied uteri, since uterine atrophy in OVX mice associates with the degree of estrogen deficiency (9). When OVX mice with normal uteri...
Fig. 2. Comparison of BMD based on uterine atrophy. (A) BMD in mice with uterine atrophy (n=28) vs mice without uterine atrophy (n=16). (B) Differences in BMD based on uterine atrophy. BMD difference is the mean BMD of mice with atrophied uteri minus the mean BMD of mice with normal uteri. BMD in mice treated with telmisartan (C) or thiazide (D) vs vehicle-treated mice. Data represent medians with inter-quartile, minimum and maximum.

Fig. 3. The effects of antihypertensive drugs on bone in OVX mice. (A) A micro-CT three-dimensional image of the trabecular architecture of a tibial proximal end from a control mouse and thiazide treated mice with normal uterine size or uterine atrophy. (B) Bone fraction of tibial proximal ends from OVX mice analyzed by micro-CT. (C) Differences in bone fraction based on uterine atrophy. Data represent medians with inter-quartile, minimum and maximum. BV, bone volume; TV, total volume.
were compared with mice with atrophied uteri, BMD decreased significantly \( (P < 0.001, \text{Fig. 2A}) \). The mean BMD loss in the atrophied uterine group was \(-21 \pm 7 \text{ mg/cm}^3\).

The effects of antihypertensive drugs on BMD loss induced by severe estrogen deficiency were assessed by calculating the BMD difference, which is the mean BMD of mice with atrophied uteri minus the mean BMD of mice with normal uteri. This difference reflected bone loss affected by severe estrogen deficiency. BMD loss in each group was as follows: control, \(-45 \pm 15 \text{ mg/cm}^3\); nifedipine, \(-34 \pm 6 \text{ mg/cm}^3\); telmisartan, \(-32 \pm 21 \text{ mg/cm}^3\); enalapril, \(-73 \pm 7 \text{ mg/cm}^3\); propranolol, \(-93 \pm 25 \text{ mg/cm}^3\); and thiazide, \(-26 \pm 10 \text{ mg/cm}^3\). When BMD was compared across all groups, there was a significant difference in multiple comparison \( (P = 0.005, \text{Fig. 2B}) \). By post hoc analysis, enalapril and propranolol increased BMD loss in mice with atrophied uteri compared with control mice. By two group analysis (i.e., vehicle-treated versus antihypertensive drug-treated), telmisartan affected bone loss moderately (\text{Fig. 2C}); however, thiazide significantly reduced bone loss by severe estrogen deficiency \( (P = 0.038, \text{Fig. 2D}) \).

Bone volume (BV) and trabecular thickness decreased in mice with uterine atrophy by micro-CT; however, BV and trabecular thickness increased in thiazide-treated mice with uterine atrophy compared with control mice (\text{Fig. 3A}). In OVX mice, BMD correlated with BV, bone fraction, trabecular number and trabecular thickness (Table 1). While there was no correlation between BMB and trabecular thickness in mice with normal uteri, an association was evident in mice with atrophied uteri \( (r = 0.503, P = 0.012) \). BMD associated most significantly with bone fraction \( (r = 0.971, P < 0.001) \).

Following multiple comparison of micro-CT parameters, only BV showed a significant difference between groups \( (P = 0.044) \). No significant differences in bone fraction were observed \( (P = 0.252, \text{Fig. 3B}) \); however, bone fraction decreased in mice with atrophied uteri treated with nifedipine, telmisartan and thiazide (\text{Fig. 3C}). Enalapril and propranolol increased bone fraction in mice with atrophied uteri compared with normal mice \( (P = 0.006) \).

### DISCUSSION

In the present study, we investigated the effects of antihypertensive drugs on BMD and bone morphometry in an animal model of postmenopausal osteoporosis. Our data showed thiazide to decrease bone loss. When data were analyzed by the severity of estrogen deficiency, thiazide and telmisartan reduced bone loss in the severely deficient estrogen group. To our knowledge, this is the first report to investigate the effects of the most commonly prescribed antihypertensive drugs on bone function in OVX mice in a single study, as suggested in the hypertension guideline (10). Because osteoporosis can coexist with hypertension, the choice of antihypertensive drugs could be influenced by their potential effect on bone and fracture risk, especially in postmenopausal women.

It is uncertain whether antihypertensive drugs affect bone directly or indirectly. Epidemiological studies report certain antihypertensive drugs such as thiazide diuretics to lower fracture risk in postmenopausal women, suggesting that antihypertensive drugs affect bone positively. For other antihypertensive drugs, the effects on bone are controversial (11). In epidemiological studies, thiazide increases BMD in postmenopausal women (12-14), and these results are consistent with our findings. Thiazide protects against age-related bone loss and osteoporotic fractures (6, 15). Cross-sectional and longitudinal observational studies show that thiazide diuretics increased BMD (12, 15); however, randomized controlled studies could not confirm the increase in BMD by thiazide (3, 14, 16). In other studies, thiazide significantly reduced all types of fractures (6, 12), suggesting that thiazide reduces sodium reabsorption and promotes calcium reabsorption. Indeed, normal calcium homeostasis can affect BMD positively (17). Thiazide also acts on bone cells directly by decreasing osteoclast differentiation (18).

The effects of beta-blocker and calcium channel blockers (CCB) on BMD in humans are controversial, with some drugs reducing fracture risk and others not affecting fracture risk (4, 13, 19-21). In OVX mice, propranolol did not reduce BMD loss in femurs (22). The results of this experiment are consistent with the earlier one. In our study, BMD was unaffected by CCB. In the case of CCB, use of non-dihydropyridine drugs was associated with a fracture risk reduction than use of dihydropyridine drugs (4). Therefore, additional studies are needed to understand the effects of CCB on bone.

Previous studies show bone to be under the influence of the renin-angiotensin-aldosterone system, with angiotensin II affecting bone homeostasis adversely. Inhibition of angiotensin II is beneficial for bone function. Treatment of angiotensin re-

### Table 1. The relationship between BMD and morphometric parameters obtained by micro-CT

| Group         | TV (μL)  | BV (μL)  | BV/TV (%) | Tb. N (μm) | Tb. Th (μm) |
|---------------|----------|----------|-----------|------------|-------------|
| Total         | -0.227   | 0.767    | 0.971     | 0.938      | 0.534       |
| BV/TV (%)     |          |          |           |            |             |
| Normal        | 0.028    | 0.629*   | 0.958*    | 0.961†     | 0.545       |
| Atrophy       | 0.258    | 0.793†   | 0.920*    | 0.821†     | 0.503*      |

*\( P < 0.05; \) †\( P < 0.01 \) (ANOVA); †Mice were grouped based on uterus size. BMD, bone mineral density; TV, total volume; BV, bone volume; Tb. N, trabecular number; Tb. Th, trabecular thickness.
ceptor blocker (ARB), olmesartan, attenuated the ovariectomy-induced decrease in BMD (23). In a recent cohort study, ARB reduced the risk of fracture in elderly women (6). Although angiotensine converting enzyme (ACE) inhibitor use was reported with higher BMD in elderly women, captopril did not increase BMD in OVX mice (24). Enalapril also did not influence bone metabolism and BMD (25). Our data suggest that ARB plays a protective role in severely deficient estrogen mice but that BMD is unaffected by an ACE inhibitor.

Our results showed that thiazide and telmisartan reduced BMD loss in OVX mice severely deficient in estrogen. These results were consistent with a recent epidemiological study where Solomon et al. reported a reduction in fracture risk by ARB and thiazide in elderly women (6). These findings suggest that ARB and thiazide are beneficial to elderly women with osteoporosis and hypertension. Because of the increasing population of elderly people with osteoporosis, the need for preventive therapy is a public health priority. Our findings are likely to help healthcare professionals prescribe antihypertensive drugs without further affecting bone function, especially in postmenopausal hypertensive women with osteoporosis.

In summary, thiazide positively affects BMD in OVX mice. Thiazide and telmisartan also reduced bone loss in severely deficient estrogen mice. Thiazide and telmisartan may be front-line therapy for hypertensive patients who are at an increased risk for osteoporosis or already have postmenopausal osteoporosis. Long-term prospective randomized studies will need to be performed to further assess the effects of antihypertensive drugs on postmenopausal osteoporosis.

DISCLOSURE

All authors state that they have no conflicts of interest.

REFERENCES

1. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23: 279-302.
2. Melton LJ 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis? JBMR Anniversary Classic: JBMR, volume 7, number 9, 1992. J Bone Miner Res 2005; 20: 886-92.
3. Ott SM, LaCroix AZ, Scholes D, Ichikawa LE, Wu K. Effects of three years of low-dose thiazides on mineral metabolism in healthy elderly persons. Osteoporos Int 2010; 19: 1315-22.
4. Rejmark L, Vestergaard P, Moskilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006; 24: 581-9.
5. Wiens M, Emminan M, Gill SS, Takkouche B. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med 2006; 260: 350-62.
6. Solomon DH, Mogun H, Gameau K, Fischer MA. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res 2011; 26: 1561-7.
7. Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 2011; 48: 451-5.
8. Boussein ML, Boyd SK, Christiansen BA, Guldberg BE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010; 25: 1468-86.
9. Otto C, Kantner I, Nubbemeyer R, Schkoldow J, Fuchs I, Krahl E, Vonk R, Schüler C, Fritzemeier KH, Erben RG. Estradiol release kinetics determine tissue response in ovariectomized rats. Endocrinology 2012; 153: 1725-33.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
11. Ilić K, Obradović N, Vujasinović-Stupar N. The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int 2013; 92: 217-27.
12. Cauley JA, Cummings SR, Seeley DG, Black D, Browner W, Kuller LH, Nevitt MC. Effects of thiazide diuretic therapy on bone mass, fractures, and falls: the Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993; 118: 666-73.
13. Lynn H, Kwok T, Wong SY, Woo J, Leung PC. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 2006; 38: 584-8.
14. Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR. The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporosis Int 2007; 18: 479-86.
15. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 133: 516-26.
16. Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, Murray MA, McNeil AR, Gamble GD. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 2000; 109: 362-70.
17. Walsh JS, Newman C, Eastell R. Heart drugs that affect bone. Trends Endocrinol Metab 2012; 23: 163-8.
18. Lalande A, Roux S, Denne MA, Stanley ER, Schiavi P, Guez D, De Verneuil MC. Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro. J Bone Miner Res 2001; 16: 361-70.
19. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC; Geelong Osteoporosis Study. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: geelong osteoporosis Study. J Bone Miner Res 2004; 19: 19-24.
20. Rejmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brisen K, Moskilde L. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 2004; 75: 365-72.
21. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC. Beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005; 20: 613-8.
22. Pierroz DD, Boussein ML, Rizzoli R, Ferrari SL. Combined treatment with a beta-blocker and intermittentPTH improves bone mass and mi-
croarchitecture in ovariectomized mice. Bone 2006; 39: 260-7.
23. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008; 22: 2465-75.
24. Liu YY, Yao WM, Wu T, Xu BL, Chen F, Cui L. Captopril improves osteopenia in ovariectomized rats and promotes bone formation in osteoblasts. J Bone Miner Metab 2011; 29: 149-58.
25. Broulík PD, Tesar V, Zima T, Jirsa M. Impact of antihypertensive therapy on the skeleton: effects of enalapril and AT1 receptor antagonist losartan in female rats. Physiol Res 2001; 50: 353-8.